Merck & Co is a global healthcare company that specializes in the development, manufacturing, and marketing of pharmaceutical products and vaccines. The company is dedicated to improving health outcomes through innovative research and is known for its focus on areas such as oncology, infectious diseases, and immunology. In addition to its pharmaceutical offerings, Merck actively engages in the discovery of new biologics and therapies, working to address some of the most pressing health challenges worldwide. Through its commitment to scientific excellence and patient care, Merck plays a critical role in advancing public health and enhancing quality of life globally. Read More
Global pharmaceutical company Merck (NYSE:MRK) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 4.9% year on year to $16....
Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2026.
Global pharmaceutical company Merck (NYSE:MRK) will be reporting results this Thursday before market open. Here’s what investors should know. Merck beat anal...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced a collaboration with nine professional baseball teams and former professional baseball players to launch the Playing with Heart educational program to help educate adults about the importance of knowing their low-density lipoprotein cholesterol (LDL-C), called “bad” cholesterol, number and the potential increased risk of heart attack or stroke.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Merck’s pending acquisition of Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN) expired at 11:59 p.m., Eastern Time, on April 23, 2026.
Let’s dig into the relative performance of Merck (NYSE:MRK) and its peers as we unravel the now-completed Q4 branded pharmaceuticals earnings season. Looking...
What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.8% in the afternoon session after the company, along with its partner Eisai, a...
Over the past six months, Merck has been a great trade, beating the S&P 500 by 32%. Its stock price has climbed to $118.94, representing a healthy 37.8% incr...
As the first-quarter earnings season of 2026 kicks off, Wall Street is bracing for a high-stakes performance that could determine the trajectory of the market for the remainder of the year. With the S&P 500 projected to deliver a robust 12.6% year-over-year earnings-per-share (EPS) growth, the index is
As of today, April 14, 2026, the biotechnology landscape is being reshaped by a singular clinical milestone that many once deemed impossible. Just twenty-four hours ago, Revolution Medicines, Inc. (Nasdaq: RVMD) released topline Phase 3 results from its RASolute 302 trial, effectively setting a new standard of care in the treatment of pancreatic cancer. For [...]
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...
As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an industry often characterized by volatile "one-hit wonders" and aggressive M&A cycles, Regeneron has carved out a unique identity as a founder-led, R&D-centric powerhouse. Currently, [...]
Daiichi Sankyo (TSE: 4568) and Merck’s, known as MSD outside of the United States and Canada, (NYSE: MRK) Biologics License Application (BLA) for ifinatamab deruxtecan (I-DXd) has been accepted and granted Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...
In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total consideration of up to $5 billion. This strategic maneuver, consisting of $3.15 billion in upfront cash and
BALA CYNWYD, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Today's Date: April 9, 2026 Introduction In the high-stakes arena of biotechnology, few companies have undergone a transformation as dramatic as ImmunityBio, Inc. (NASDAQ: IBRX). Long viewed by Wall Street as a speculative "story stock" with a complex corporate structure, the company has pivoted sharply into a commercial powerhouse. As of early 2026, ImmunityBio is [...]
